Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00122317 · ClinicalTrials.gov registry record · Phase 3
Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)
A Phase 3 study of Paroxysmal Hemoglobinuria, Nocturnal, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 187
- Enrollment target
- 20
- Study locations
NCT00122317 is a Phase 3 study of Paroxysmal Hemoglobinuria, Nocturnal that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 187 participants. The trial reports 20 study locations across 17 states.
The verdict
NCT00122317, a Phase 3 study of Paroxysmal Hemoglobinuria, Nocturnal, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 187 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the long-term safety of eculizumab in patients with transfusion dependent hemolytic PNH.
Conditions Studied
Interventions
- DRUG eculizumab
Study Locations (20)
Maryland
- Johns Hopkins University Medical Center - Baltimore
- National Heart, Lung, and Blood Institute, National Institutes of Health - Bethesda
New York
- NYU Clinical Cancer Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Other
- Royal Melbourne Hospital, Department of Clinical Haematology & Medical Oncology - Parkville
- Ucl St. Luc, Hematology Department - Brussels
California
- Stanford University Medical Center, Division of Hematology - Stanford
Connecticut
- Hartford Hospital, Cancer Clinical Research Office - Hartford
Florida
- Cleveland Clinic Florida, Department of Clinical Research - Weston
Indiana
- Indianapolis University Cancer Center - Indianapolis
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 187 participants |
| Start Date | 2005-05 |
| Est. Completion | 2008-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00122317
The ClinicalTrials.gov registry entry for NCT00122317 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Paroxysmal Hemoglobinuria, Nocturnal appearing as the primary indexed condition, and to 1 intervention - of which eculizumab is the first listed.
NCT00122317 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Maryland, New York, Other.
Frequently Asked Questions
What is clinical trial NCT00122317 about?
NCT00122317 is a clinical study titled "Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)". The purpose of this study is to evaluate the long-term safety of eculizumab in patients with transfusion dependent hemolytic PNH.
What is the current status of trial NCT00122317?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 187 participants. The study started on 2005-05. Estimated completion is 2008-10.
What conditions does trial NCT00122317 study?
This clinical trial studies the following conditions: Paroxysmal Hemoglobinuria, Nocturnal.
What interventions are being tested in trial NCT00122317?
The interventions under investigation include: eculizumab (DRUG).
Who is sponsoring clinical trial NCT00122317?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00122317 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Paroxysmal Hemoglobinuria, Nocturnal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.